UPDATE: Unilabs Offering Genomic Health's Oncotype DX Breast Cancer Test in UK | GenomeWeb

The story has been updated to clarify that the Oncotype DX breast cancer test will be conducted at Genomic Health's laboratory in California.

NEW YORK (GenomeWeb News) – Swiss-based diagnostics firm Unilabs said today that it is now offering Genomic Health's Oncotype DX breast cancer test at partner clinics and hospitals.

As part of its agreement with Genomic Health, physicians can send their patients' tissue samples to the Unilabs HIS laboratory. All tests will be sent to Genomic Health's centralized laboratory where the Oncotype DX testing will be done.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.